Fig. 01 -

Title Slide

Fig. 02 -

Disclosures

Fig. 03 -

Breathing Disturbances

Fig. 04 -

Personalized Treatment

Fig. 05 -

CSA & Periodic Breathing

Fig. 06 -

International Classification

Fig. 07 -

Hypocapnic

Fig. 08 -

Apnoea Threshold

Fig. 09 -

Loop Gain

Fig. 10 -

Case Report

Fig. 11 -

Co-Existing Obstructions

Fig. 12 -

CPAP not effective

Fig. 13 -

CanPAP trial

Fig. 14 -

CanPAP Post-hoc analysis

Fig. 15 -

What does it mean?

Fig. 16 -

Algorithms

Fig. 17 -

Moving window

Fig. 18 -

Common Features

Fig. 19 -

Max Pressure

Fig. 20 -

EPAP Increase

Fig. 21 -

IPAP Increase

Fig. 22 -

3 Night Examples

Fig. 23 -

Clinical Practice

Fig. 24 -

Cheyne-Stokes Breathing

Fig. 25 -

Heart Failure Patients

Fig. 26 -

Clinical and Financial Impact

Fig. 27 -

ASV in Heart Failure

Fig. 28 -

Therapeutical Options

Fig. 29 -

SERVE-HF trial

Fig. 30 -

SERVE-HF Additional Evaluations

Fig. 31 -

SERVE-HF trial

Fig. 32 -

Controversial Data?

Fig. 33 -

Arrhythmias in HF

Fig. 34 -

Change in AF

Fig. 35 -

Meta-Analysis

Fig. 36 -

Advent-HF

Fig. 37 -

Compliance and Predictors

Fig. 38 -

European Society of Cardiology

Fig. 39 -

Heterogenous Results

Fig. 40 -

Treatment-Emerging CSA

Fig. 41 -

CPAP-Emergent CSA

Fig. 42 -

Randomized Controlled Trial

Fig. 43 -

ASV vs. NIV

Fig. 44 -

Diagnosis

Fig. 45 -

Chronic Opioid Use

Fig. 46 -

Atactic Breathing

Fig. 47 -

Respiratory Drive: Loop Gain

Fig. 48 -

Opioid-Induced CSA

Fig. 49 -

Case Report

Fig. 50 -

Case Report Results

Fig. 51 -

Multiple Symptoms

Fig. 52 -

CPAP 6 & 7 mbar

Fig. 53 -

Male Patient Results

Fig. 54 -

Therapeutic Algorithm & Closing